

PATIENT VISIT NOTE

Name	Ms SATVIKI PATIDAR		
UHID	9000701818	Visit No	9012506104028
Age /Sex	6 Y / F	Visit Date	10-06-2025 12:09 PM
Doctor Name	Dr. Deenadayalan Munirathnam	Department	Paediatric Haematology,Oncology and BMT

Chief Complaints :

Diffuse low grade glioma - hypothalamic/optic pathway

HOPI :

- Seizures since Sept 2023- evaluated
- Initial MRI - Jan 2024 showed Large left gangliocapsular SOL extending in to the left temporal lobe. Repeat MRI in April 2024 - Similar lesion with no gross change in size /contrast enhancement, MRS - Choline peak.
- F/S/O - Glioma ? Low grade. EEG done twice - Normal.
- Remained on follow up with 3 monthly MRI
- Follow up MRI brain with contrast with tumor protocol done on 15/2/25 showed - Persistent large and poorly marginated intra axial SOL involving basal ganglia, thalamus, midbrain and the medial temporal lobe on the left side - approx 20% of lesion resected.
- Underwent left pterional craniotomy with microsurgical excision of mesial temporal SOL on 22/4/25.
- HPE - Diffuse low grade glioma (CNS grade 2) - IDH1 negative, ATRX and H3K27me3 retained, Ki67 <1%.
- MGMT promoter methylation status negative, 1p/19q co-deletion negative.
- NGS panel - BRAF/DBN1 fusion positive.

Examination :

Doctor Notes :

Currently seizure free, clinically stable.

Visually impaired in one eye, but no other apparent neurological deficit.

Doctor Advise :

1. Considering the residual tumour, this child would benefit from adjuvant chemotherapy.
2. As the NGS panel shows a BRAF/DBN1 fusion (which appears novel, not reported in literature), and not a BRAF mutation, Dabrafenib is contraindicated and cannot be considered as combination therapy (Ref: Kieran et al) with Trametinib.
3. Tovorafenib would ideally be suitable in this case (FDA approved last year after FIREFLY-1 trial). However the drug is not available in India and will have to be imported. The approx cost would be 40000 USD for one box of tablets.
4. We suggest starting Trametinib 0.5 mg once daily, with monitoring of blood counts once a month, and MRI brain every 3 months. A screening 2D ECHO is recommended before starting Trametinib.

Dr. Deenadayalan Munirathnam MBBS, DCH, DNB, Fellowship(IAP), FNB
 Paediatric Haematology,Oncology and BMT
 HOD and Clinical lead
 56074